Progenics Pharmaceuticals (PGNX +30%) soars after reporting Q4 losses narrowed to $0.01 per...

|About: Progenics Pharmaceuticals Inc. (PGNX)|By:, SA News Editor

Progenics Pharmaceuticals (PGNX +30%) soars after reporting Q4 losses narrowed to $0.01 per share, compared with the prior-year period's loss of $0.32 per share. Revenues also jumped to $8.9M, up from $2.3M in the same period last year, and above analysts estimates of $1.16M. The company attributes the boost in sales from partnering two of its proprietary research programs.

Subscribe for full text news in your inbox